Pacira BioSciences Reports First Quarter 2020 Financial Results and Business Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Wall St futures pause after AI rally, focus on Mideast tensions
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Pacira Pharma (PCRX) Tops Q1 EPS by 22c, Revenues Beat
May 7, 2020 8:09 AM EDTPacira Pharma (NASDAQ: PCRX) reported Q1 EPS of $0.53, $0.22 better than the analyst estimate of $0.31. Revenue for the quarter came in at $105.7 million versus the consensus estimate of $102.82 million.
First Quarter 2020 Financial Results
Total revenues were $105.7 million in the first quarter of 2020, a 16% increase over the $91.3 million reported for the first quarter of 2019.EXPAREL net product sales were $101.3 million in the first quarter of 2020, a 12% increase over the $90.6 million reported for the first quarter of 2019.First quarter iovera° net product sales were $2.3 million. Pacira began recognizing sales of iovera° in April 2019... More